Unnamed Bidders Approach Sobi

Getinge has announced an agreement to acquire 100% of Paragonix Technologies for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million. The acquisition aligns with Getinge’s broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already […]

The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark, it states. “Scandinavian CRO is a great addition to our Labquality family completing our CRO business platform. Now, we are a full service CRO company, and we can continue […]

Genovis has announced the successful divestment of its antibody business to Leinco Technologies, a developer of antibodies for research and diagnostics. The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business, it states. The antibody business, while valuable, was deemed non-core to the company’s long-term growth […]

This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas, it states. Following the investment, Genovis will own 25 percent of Sequrna. As part of the transaction, the parties have agreed to a call option with an end […]

AddLife acquires BonsaiLab, a Spanish distributor in the field of cell and molecular biology. The company, with current revenues of EUR 8 million, has operations in Spain and Portugal and will be included in AddLife’s business area Labtech. BonsaiLab will be included in the Biomedical and Research business unit, a part of the Labtech business […]

Center for Translational Research (CTR) expands by acquiring Zelmic, the GMP-approved Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specialized in development of topical and transdermal pharmaceutical formulations and drug delivery. The acquisition further expands CTRs portfolio, within pharmaceutical, regulatory, and clinical development to the CTR group, the company states. “The addition […]

Perpetua Medical has entered a letter of intent with the shareholders of ES-Medical regarding an investment in the company and acquisition of shares in ES-Medical. Perpetua Medical’s ownership is intended to amount to 70 percent of the shares in the company after the transaction, with an option to acquire the remaining 30 percent after three […]